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Abstract: Metabolomics is a branch of ‘omics’ sciences that utilises a couple of analytical tools
for the identification of small molecules (metabolites) in a given sample. The overarching goal of
metabolomics is to assess these metabolites quantitatively and qualitatively for their diagnostic,
therapeutic, and prognostic potentials. Its use in various aspects of life has been documented. We
have also published, howbeit in animal models, a few papers where metabolomic approaches were
used in the study of metabolic disorders, such as metabolic syndrome, diabetes, and obesity. As the
goal of every research is to benefit humankind, the purpose of this review is to provide insights into
the applicability of metabolomics in medicine vis-à-vis its role in biomarker discovery for disease
diagnosis and management. Here, important biomarkers with proven diagnostic and therapeutic rel-
evance in the management of disease conditions, such as Alzheimer’s disease, dementia, Parkinson’s
disease, inborn errors of metabolism (IEM), diabetic retinopathy, and cardiovascular disease, are
noted. The paper also discusses a few reasons why most metabolomics-based laboratory discoveries
are not readily translated to the clinic and how these could be addressed going forward.
Keywords: metabolomics; metabolites; biomarkers; analytical tools; diseases; diabetes; obesity
1. Introduction
Metabolomics is one of the latest on the list of ‘omics’ sciences after genomics, pro-
teomics, and transcriptomics and combines high-throughput analytical techniques with
bioinformatics. It deals with quantitative and qualitative assessments of metabolites, which
are important intermediates and end products of metabolism [1]. The goal of this scientific
approach is not just to decipher what pathological processes or perturbations underlie a
given disease entity but also to predict responses of such conditions to therapeutic inter-
ventions. Metabolomic analyses allow us to distinguish between normal and pathological
pathways, thereby helping in making disease diagnosis and predicting prognosis [2]. Given
the fact that metabolites are a downstream expression of the various changes that occur in
the genome, the proteome, and the transcriptome, they can closely represent the pheno-
typic fingerprints of an organism at any point in time. The totality of these small-molecule
metabolites that are found in a biological sample at a given physiological period and that
give an express functional summary of all the metabolic activities going on in a particular
biological sample is termed metabolome [1,3,4]. One notable advantage of metabolome
over genome is its ability to reflect the environmental influences [5] and to give a snapshot
of the patho-physiological condition of the individual at a specific point in time [6]. In
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animal models, we have utilised a couple of these tools to study some metabolic disorders,
such as metabolic syndrome, diabetes, and obesity [7–9]. Our goals in those studies were to
gain better insights into the biochemical and pathological processes that are perturbed and
to inform the development of more improved therapeutic agents in the management of
those disease conditions in humans. Metabolomic tools offer the advantages of being fast,
cheap, and sensitive. However, the data generated by these tools mean nothing unless they
are properly analysed for the construction of biochemical pathways and for understanding
how these pathways interact in both diseased and nondiseased states [10].
There are several approaches to metabolomics, each of which could be achieved
by either mass spectrometry (MS), nuclear magnetic resonance (NMR) spectroscopy, or
Fourier-transform infrared (FTIR) spectroscopy techniques (see Figure 2). Examples of such
approaches include metabolomic fingerprinting, metabolic profiling, metabolic footprint-
ing, target analysis, and flux analysis, each playing significant roles in understanding toxi-
cological mechanisms and disease processes in living organisms [1,11,12]. Metabolomics is
an equally valuable tool for new drug discovery; biomarker discovery for early disease
diagnosis, such as diagnosis of rheumatoid or osteoarthritis [13–16], osteoporosis [17],
cardiovascular disease [18], and Alzheimer’s disease (AD) [19,20]; monitoring of cancer
prognosis, diagnosis, and treatment [20–28]; inborn errors of metabolism (IEM) [29]; and
a host of others. Metabolomics also has applications in such areas as physiology, safety
evaluation of new drugs, nutrition, and environmental assessment. The aim of this re-
view is to give an overview of various metabolomic approaches and to highlight some
recent biomarker discoveries for disease diagnosis, treatment, and prognosis using these
analytical tools.
1.1. Metabolomic Processes/Workflow
For a successful targeted or untargeted metabolomic study, the following steps, which
have been previously described elsewhere [30], are followed: experimental design; sam-
ple collection, preparation, and metabolite extraction; data acquisition and processing;
statistical analysis; and biomarker discovery. Experimental design, the first step in the
metabolomic workflow, is informed by the nature of the biological specimen to be used.
Hence, questions such as whether human or animal samples or models will be used,
whether it will be cell based, tissue based, the whole organism, fluid, or growth medium
based, must be answered. Additionally, the metabolomic approach to be employed (tar-
geted or untargeted) and the gap the study attempts to bridge or the problem it seeks
to solve are important considerations in designing the experiment. Once this has been
settled, the researcher moves to the next phase, namely, sample collection, preparation,
and metabolite extraction. For an MS-based approach, this stage is often required and may
involve liquid–liquid extraction, solid-phase extraction, or filtration technique, depending
on the biological samples one is dealing with. For an NMR-spectroscopy-based approach,
little or no sample preparation may be required. The third step involves data acquisition
and processing. This involves the use of analytical platforms such as MS, NMR, and FTIR
spectroscopy. The fourth step is statistical analysis. Here, either or both a univariate analyt-
ical tool (e.g., t-test, ANOVA, fold changes) and a multivariate analytical approach (i.e.,
use of PCA, PLS-DA, OPLS-DA) could be employed. The last step is biomarker discovery.
Here, metabolites with differential expressions (overexpression or downregulation) are
identified using standardised bioinformatics tools and databases. Figure 1 below gives
a summary of the processes involved and the research questions to ask for a successful
metabolomic study.
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Figure 1. Metabolomic workflow. The first stage involves experimental design, followed by sample collection, preparation,
and metabolite extraction. Next is acquisition and processing of data, then data analysis, and finally, making sense of the
data through biomarker discovery.
1.2. Analytical Platforms for Data Acquisition and Processing: Strengths and Limitations
To have a better understanding of the metabolic milieu of biological systems, analytical
platforms are employed to identify and quantify small-molecular-weight metabolites ahead
of further analysis of the data generated by the platforms. The two most predominantly
utilized analytical tools for metabolomic studies are NMR and MS spectroscopy [1,31].
The MS approach is usually coupled with chromatographic techniques, such as liquid
chromatography (LC–MS), especially high-performance liquid chromatography (HPLC–
MS), and gas chromatography (GC–MS) [8,32] with varying degrees of sensitivity. The
MS technique can also be coupled to capillary electrophoresis (CE–MS). Although NMR
offers such benefits as easy sample preparation, shorter time for sample analysis, easily
identifiable metabolites from analysis of spectra, and better sample recovery, it is only able
to analyse less variety of metabolites, and only a few comprehensive metabolite databases
for NMR-based metabolomics are currently available [6]. The ease of sample preparation
and the reproducibility of result have made NMR spectroscopy, therefore, a highly sought-
after approach for the structural analysis of metabolites [33]. On the other hand, MS-
based techniques can analyse a wide range of metabolites following chromatographic
separation, and several comprehensive metabolite databases are presently available [17].
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Nonetheless, the sensitivity of MS-based platforms depends on the chromatographic
separation technique with which it is combined [33]. For instance, while GC–MS gives
better chromatographic resolution of the metabolites, LC–MS is the preferred combination
when it comes to metabolite coverage and sensitivity [33–36]. The MS approach is, however,
not without its drawbacks, namely, the sample preparation is more rigorous, the technique
could fragment the samples, making recovery almost impossible; and there is much
difficulty identifying unknown compounds on its spectra [6]. Metabolite identification
and quantification using the NMR approach (e.g., proton NMR, 13C NMR, 19F NMR, 31P
NMR spectroscopy) have been improved in recent years. Of note is the introduction of
cyroprobes and microprobes, which have reduced the detection limit by a factor of about 3
to 5 [18]. This approach is further enhanced by using two-dimensional total correlation
spectroscopy (2D TOCSY) for the confirmation of assigned peaks. The 2D TOCSY spectrum
usually shows the correlations between two frequency axes that are derived from two-
dimensional Fourier transformations. Nuclear Overhauser effect spectroscopy (NOESY),
heteronuclear single quantum coherence (HSQC), exchange spectroscopy (ES), and J-
spectroscopy (JS) are a few other examples of two-dimensional NMR that have been
used to improve NMR-based data acquisition and metabolite structure analysis, thereby
providing better information than one-dimensional NMR, especially for small-molecule
metabolites [37–39]. Additionally, better outcomes can be achieved by combining two forms
of 2D NMR, such as NOESY and HSQC, TOCSY, and HSQC; by combining MS with NMR
spectroscopy [40]; or by using three-dimensional NMR methods. Apart from NMR and
MS platforms, another tool that is also being increasingly utilised for metabolomic studies
is FTIR spectroscopy [32]. In general, identification of metabolites is based on their mass,
mass/charge ratios, and retention time [6]. With these parameters in place, both known and
unknown compounds could be identified by comparing them with metabolite databases,
such as Metlin/XCMS and the Human Metabolome Database [6]. For compounds with
unknown MS and NMR spectra characteristics, an untargeted approach and chemometrics
could be applied for metabolite pattern identification [6]. A brief description of the foremost
analytical platforms for metabolomic studies is shown in Figure 2.
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Figure 2. Summary of the major analytical platforms for metabolomic studies in human and animal
samples. The figure depicts the three most often employed platforms for etabolomic studies—MS,
NMR, and FTI spectroscopy. The MS-based approach involves c upling with liquid chromatography
(LC), g s chromatography (GC), or capillar electrophoresis (CE).
1.3. Metabolomic Data Analysis
Profiling the metabolites in each biological entity is incomplete without an accu-
rate data measurement and precise interpretation of the information garnered from such
exercise. Metabolomic data analysis encompasses feature extraction, compound iden-
tification, statistical analysis, and interpretation. Use of multivariate analyses, such as
PCA, PLS-DA, and OPLS-DA, is key to achieving this. Together, these pattern recog-
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nition analytical techniques (PCA, PLS-DA, and OPLS-DA) help to comprehensively
assess the metabolites that are present in any given biological sample or that are asso-
ciated with a specific disease condition [11]. Scores from PCA plots show a scattering
of the samples, and when they are clustered together, it shows that the metabolites are
alike; otherwise, they are dissimilar [11]. PLS-DA, on the other hand, is a very ver-
satile algorithm with a better predictive and descriptive advantage over PCA. It seeks
to maximise the covariance between the classes much better than PCA. Bioinformatics
tools available for metabolomic data analysis, pathway analysis, and interpretation in-
clude Metabox (available for free at http://kwanjeeraw.github.io/metabox/ (accessed
on 10 January 2020) under the GPL-3 license) [30] and MetaboAnalyst (available at
http://www.metaboanalyst.ca/MetaboAnalyst (accessed on 10 January 2020)) [20]. Others
include SECIMTools, Meta XCMS, XCMS, XCMS2, MetAlign, MZmine for data processing
of MS data, and MetDAT for statistical analysis and pathway visualization.
2. Results
This mini review focuses on five disease conditions in which metabolomic tools have
been utilised for diagnosis, treatment, or prognosis prediction. The first four of these
conditions are chronic non-communicable diseases in adults, while the fifth is a group of
inborn errors of metabolism in children. These medical disorders are Parkinson’s disease
(PD), diabetic retinopathy, Alzheimer’s disease (AD)/dementia, cardiovascular disease,
and inborn error or metabolism (IEM). Out of the 26 publications that were included in this
review, 3 were adjudged to be relevant to our research interest with respect to PD [41–43],
5 with respect to diabetic retinopathy [30,44–47], 2 for AD [16,46], 14 for cardiovascular dis-
ease [18,48–58], and 2 for IEM [59,60]. Of the 3 most often utilised platforms for metabolic
profiling, MS spectroscopy (coupled with other separation techniques) ranks first, being
employed for biomarker discovery in 17 out of the 26 studies identified, and accounting
for 65.4% of all studies. This was followed by NMR spectroscopy, which accounted for
just 19.2% (5 studies) of cases. In terms of statistical analysis, multivariate analysis in-
volving PCA and/or PLS-DA was utilised in 6 studies [41,46,47,49,54,61], followed by
the use of receiver operating characteristic (ROC) curve or area under the curve (AUC)
analysis [30,42,50,56,58]. Details of the study characteristics, the analytical tools employed,
and the respective biomarkers identified are summarised in Tables 1 and 2, respectively.
Table 1. The proportion of analytical tools that were employed in the included studies.
S/No Analytical Tool Proportion (%)
1 Mass spectrometry based 65.4
2 NMR spectroscopy based 19.2
3 Others 15.4
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Table 2. A few metabolic biomarkers of diagnostic and prognostic significance.
S/N Disease Condition Metabolic Biomarkers/Pathway Analytical Platform Statistics References
1 Parkinson’s disease
Long-chain acylcarnitine CE–TOF/MS ROC [42]
Kynurenic acid, quinolinic acid, ratio of kynurenic
acid/kynurenine, ratio of quinolinic
acid/kynurenic acid
UPLC–TOF/MS OPLS-DA [41]
3-hydroxykynurenine/kynurenic acid ratio LC–MS t-test [43]




Perturbations in carbohydrate metabolism, lipid
contents, biomarkers associated with




feature selection (FFS), and
Mann–Whitney U tests
[44]
Alterations in glucose and purine metabolism;
activation of the hexose monophosphate shunt Untargeted MS [45]
Fumarate, uridine, acetic acid, and cytidine LC–MS Area under the curve (AUC) [30]
Plasma glutamine and glutamate GC–MS/UPLC–MS Multivariate analysis [46]
Activation of alanine, aspartate, and glutamate
metabolic pathways NMR-based spectroscopy
PCA, heat map analysis,
average change analysis [47]
4 Cardiovascular disease




metabolism, and carnitine shuttle pathway Untargeted metabolomics ‘Meet in the middle’ statistics [48]
Acetylglycine, threoninyl-glycine, glutarylglycine,
and nonanoylcarnitine UPLS–Q/TOF–MS
ROC with AUC, sensitivity,
specificity [62]
Phosphatidylserine, C16-sphingosine, N-methyl
arachidonic amide, N-(2-methoxyethyl) arachidonic
amide, linoleamidoglycerophosphate choline,
lyso-PC (C18:2), lyso-PC (C16:0), lyso-PC (C18:1),
arachidonic acid, and linoleic acid
UPLS–Q/TOF–MS PCA, PLS-DA [49]
Metabolites 2021, 11, 418 7 of 15
Table 2. Cont.
S/N Disease Condition Metabolic Biomarkers/Pathway Analytical Platform Statistics References





Acylcarnitine MS Paired t-test, generalisedestimating equations [52]
Urea cycle/amino group, tryptophan,
aspartate/asparagine, lysine, tyrosine, and carnitine
shuttle pathways
LC–MS t-test, chi-square [53]
Asparagine, tyrosine, xylose, for ischaemic stroke LC–MS Wilcoxon test, OPLS-DA [54]
Sphingomyelin for incident ischaemic stroke LC–MS Paired Wilcoxon rank test [63]
Citrate, tyrosine, 2- and 3-hydroxybutyrates for
acute heart failure NMR spectroscopy Logistic regression analysis [55]
23 metabolites, with higher levels of 7
(3-hydroxybutyrate, proline, acetate, creatinine,
acetone, formate, mannose) and lower levels of 2
(valine, histidine) as predictors of mortality
NMR spectroscopy ROC, multivariateregression/PCA, Cox models [56]
104 metabolites, with lower levels of 7 (pelargonic
acid, glucosamine/galactosamine, thymine,
3-hydroxybutyric acid, creatine, 2-aminoisobutyric
acid, hypoxanthine) as correlates for coronary artery
disease
CE–TOF/MS Unsupervised PCA [57]
2-Hydroxycaproate, gluconate, and sorbitol for
atherosclerosis UPLC–MS ROC [58]
13 metabolites, 2 of which (phenylalanine and
acetate) were significant predictors of heart failure
hospitalisation
NMR spectroscopy t-test, Cox proportional hazardregression [64]
5 Inborn errors of metabolism
Mannosyl-β1,4-N-acetylglucosamine, the
biomarker for β-mannosidase deficiency; correctly
diagnosed 90% of IEM cases
UHPLC–Orbitrap–MS Z-scores [60]
Correctly identified 42 out of 46 IEM cases LC–QTOF–MS Two-sided t-tests [59]
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3. Discussion
A combination of metabolomic study and multivariate data analysis offers tremendous
advantages of understanding specific pathways of metabolism that are perturbed in a
particular disease state [10,16]. Information derived from such scientific efforts goes a long
way in providing insights into useful diagnostic and therapeutic metabolite biomarkers
for effective disease management [14] and prognostication. Below are a few examples of
disease conditions with their recently documented clinically relevant metabolic biomarkers.
3.1. Parkinson’s Disease
Currently, PD affects well over 4 million people globally, and sadly, this figure is
expected to double over the next few decades [65]. This progressive neurodegenerative
disorder, affecting mostly the adult population, is difficult to manage. Despite many years
of research, a lot is still unknown about the aetiology of the disease [66]. The reason for
this may be that it is a multifactorial disease, and that multiple mechanistic pathways
may be involved in its causation [21]. In addition, only a few disease-modifying therapies
are presently available. This is largely secondary to absence of effective biomarkers that
could aid in both disease diagnosis and treatment [66]. Existing diagnosis efforts rely
heavily on symptoms, patient history, and clinical examination, making misdiagnosis
inevitable in clinical settings [66]. A better diagnostic approach that is simple, fast, and
less invasive is therefore needed, and metabolomic tools have been reported to show great
assurance in this regard [41]. In a recent study, Saiki et al. [42] carried out a metabolomic
analysis using capillary electrophoresis and liquid chromatography coupled with MS on
blood samples (a less invasive procedure compared with the use of CSF) and identified
18 PD-specific metabolites. In this research, significant decreases in the levels of seven
long-chain acylcarnitines were identified as promising metabolite biomarkers in PD diag-
nosis. In another study, Havelund et al. [43] utilised LC–MS to assess levels of kynurenine
metabolites in both plasma and cerebrospinal fluid samples of healthy individuals and
compared them with those of three categories of PD patients: PD patients not on medica-
tions, PD patients undergoing treatment using L-3,4-dihydroxyphenylalanine (L-DOPA)
who have developed dyskinesia, and PD patients who are yet to develop dyskinesia de-
spite prolonged use of L-DOPA. Their findings showed an approximate fourfold rise in
the ratio of 3-hydroxykynurenine to kynurenic acid in plasma samples and a significant
decrease in anthranilic acid levels in both plasma and CSF samples of PD patients with
L-DOPA-induced dyskinesia. The study further reported a twofold increase in the levels of
5-hydroxytryptophan in all of the L-DOPA-treated PD patients (with or without dyskine-
sia). The researchers concluded that a higher 3-hydroxykynurenine/kynurenic acid ratio in
plasma could serve as a biomarker in the diagnosis of dyskinesia induced by L-DOPA [42].
In another targeted metabolomic study that compared the levels of some metabolites in
PD patients in early Hoehn–Yahr stage ≤ 2 with those in the advanced stage of the disease
(Hoehn–Yahr stage > 2), Chang et al. [41] reported that the former category of patients had
lower levels of kynurenine acid (KA) and kynurenine acid/kynurenine ratio and higher
levels of quinolinic acid (QA) and QA/KA ratio when compared with patients in the early
stage of the disease and normal controls, demonstrating significant metabolite signatures
that could serve as biomarkers in the plasma of PD patients.
3.2. Diabetic Retinopathy
Diabetic retinopathy is one of the major complications that result from chronic, long-
standing diabetes mellitus among individuals who suffer from this medical condition.
Mazumder et al. [44], in a study involving human subjects, utilised FTIR spectroscopy to
analyse serum samples and identified 12 important biomarkers with potentials to signif-
icantly discriminate between diabetic patients with retinopathy and those without this
complication. Two of these biomarkers were associated with carbohydrate metabolism,
5 with alterations in lipid contents, 4 with protein phosphorylation, and 3 with the amide II
group [44]. An untargeted mass spectrometry metabolomic approach was equally applied
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for the analysis of the vitreous humour of patients with rhegmatogenous retinal detach-
ment, diabetic retinopathy, and healthy subjects in a recent study [45]. Here, significant
alterations in glucose metabolism and activation of the hexose monophosphate shunt were
reported. In addition, alteration in purine metabolism (characterised by a decrease in
xanthine and elevation in purine-related compounds, such as inosine, hypoxanthine, urate,
and allantoate) was seen in those with diabetic retinopathy but absent in those with retinal
detachment and healthy controls. The researchers concluded that significant perturbations
in vitreous humour metabolism in diabetic retinopathy account for the characteristic oxida-
tive stress seen in patients with this complication and show how the vitreous metabolite
profile could be affected by the disease [45]. Again, noteworthy diagnostic biomarkers
have been identified for proliferative diabetic retinopathy, a leading cause of irreversible
blindness in adults with type 2 diabetes mellitus [30]. In a large population-based study
aimed at profiling the plasma metabolites of patients with proliferative diabetic retinopathy
using liquid chromatography–mass spectrometry, Zhu and others [30] reported alterations
in the metabolism of 63 metabolites, out of which 4 metabolites, namely, fumaric acid,
uridine, acetic acid, and cytidine (with areas under the curve of 0.96, 0.95, 1.0, and 0.95,
respectively), were identified as candidate biomarkers for this sight-threatening condi-
tion. According to the researchers, this study was the first to report fumarate as a novel
biomarker in relation to diabetes or diabetic retinopathy diagnosis [20]. Using a combi-
nation of gas chromatography time-of-flight mass spectrometry and ultraperformance
liquid chromatography–quadrupole time-of-flight mass spectrometry tools, Rhee et al. [46]
identified plasma glutamine and glutamate as potential biomarkers for predicting the de-
velopment of diabetic retinopathy in patients with long-standing diabetes. That significant
oxidative stress and alteration in the pathway of glutamate metabolism are associated with
diabetic retinopathy was equally reported by Jin et al. [47]. Other metabolites that have
shown relevance as important biomarkers for making diagnosis or predicting prognosis in
diabetic retinopathy include lactic acid, succinic acid, 2-hydroxybutyric acid, asparagine,
dimethylamine, histidine, threonine, and glutamine [47].
3.3. Alzheimer’s Disease (AD)/Dementia
This is a progressive degenerative disease affecting the brain. It is a leading cause of
morbidity and mortality among people with diabetes mellitus and hypertension globally.
AD is a major cause of vascular dementia, a very debilitating condition characterised
by a progressive decline in memory and behavioural and social skills, especially in the
elderly. Presently, biomarkers for early disease diagnosis are inadequate in that they are
mostly invasive, time-consuming, and expensive [2]. To this end, a blood-based approach
for diagnosing AD using metabolic fingerprinting has been proposed [67]. Metabolomic
approaches have shown great promise in bridging this gap, especially with its application
on blood samples, a less invasive and cheaper mode of sample collection, in advanced
stages (e.g., with dementia) of the disease [68]. In a recent large population study aimed
at assessing the association between plasma total tau levels, cognitive decline, and risk
of mild cognitive impairment in dementia, Mielke et al. [61] reported that higher total
tau levels were associated with significant reduction in cognition, memory, attention, and
visuospatial ability of the patients, while this association is independent of a rise in the
level of brain amyloid beta (Aβ) peptides. Identification of diagnostic biomarkers in
the saliva of individuals with AD has equally been reported using proton-NMR-based
metabolomics [20]. In this pilot study, significant concentration changes in the levels of
22 metabolites were observed in the saliva samples of those with mild cognitive impairment
and dementia compared with healthy control. The implication of these findings is that, by
simply collecting blood samples or saliva from an individual with Alzheimer’s disease,
progression to vascular dementia or other cognitive impairment could be detected early
easily and managed promptly.
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3.4. Cardiovascular Disease
Cardiovascular disease (CVD) is a major cause of stroke and sudden death, especially
among adults with hypertension. Notwithstanding the several risk managements, pre-
ventive measures, and treatment modalities that have been initiated for CVDs, patients
have continued to die from cardiac-related complications, hence the need to identify novel
therapeutic strategies for managing this condition [69]. Metabolomics has offered a very
promising alternative to surmounting this problem by making possible the identifica-
tion of important biomarkers for diagnosis and risk assessment for CVD development
even before patients begin to show overt symptoms [61]. In a recent study involving the
use of an untargeted metabolomic approach, namely, stable isotope dilution tandem MS
(LC–MS/MS), Li et al. [18] identified trimethyllysine as a predictor of incident cardiovascu-
lar risk. Using Spearman’s correlation analyses, the researchers discovered a significant
correlation between this biomarker (trimethyllysine) and the artherogenic metabolite
trimethylamine N-oxide. In another untargeted metabolomic study aimed at finding the
association between chronic air pollution exposure and risk of developing bronchial asthma
and cardiovascular disease, Jeong and others [48] identified three important pathways
of metabolism, namely, linoleate, glycosphingolipid, and carnitine shuttle pathways as
key mediators of these health effects among those who were exposed. The strength of
this study, which utilised the novel ‘meet in the middle’ statistical approach, lies in the
fact that it was prospective in nature (namely, a case–control study nested in longitudi-
nal cohorts) [34]. Metabolomic tools have also been employed to study the pathology
of myocardial infarction (MI). Zhu et al. [49] examined the plasma of MI patients us-
ing UPLS–Q/TOF–MS and identified 10 metabolites that satisfactorily distinguished MI
patients from healthy controls. These metabolite biomarkers include C16-sphingosine,
N-methyl arachidonic amide, phosphatidylserine, N-(2-methoxyethyl) arachidonic amide,
linoleamidoglycerophosphate choline, lysophosphatidylcholine (C18:2), lysophosphatidyl-
choline (C16:0), lysophosphatidylcholine (C18:1), arachidonic, and linoleic acid, as well as
perturbations in energy, fatty acid, and phospholipid metabolism. Aside from its poten-
tial in discriminating between persons with myocardial infarction and healthy controls,
metabolomics has equally been shown to have the ability to predict the risk of developing
acute myocardial infarction with fragmented QRS in patients who undergo percutaneous
coronary intervention (PCI) [50]. In a recent hospital-based cohort study, Li et al. [50]
performed a global metabolic profiling using UPLS–Q/TOF–MS on a cohort of 136 non-
coronary artery disease and 118 acute myocardial infarction (AMI) patients undergoing PCI
and identified four metabolites as important biomarkers. These metabolites (acetylglycine,
threoninyl-glycine, glutarylglycine, and nonanoylcarnitine) were reported to significantly
discriminate between AMI with fragmented QRS and that without it. In another study
involving 79 patients with heart failure, Chen and others [52] reported that significant per-
turbations in fatty acid metabolism are associated with acute decompensation in this patient
category. In this case–control hospital-based study, acylcarnitine was identified and quanti-
fied as an important metabolite biomarker using MS spectroscopy. Serum concentrations of
three other metabolites, namely, citrate, tyrosine, and 2- and 3-hydroxybutyrates, have also
been linked to increased mortality rate among patients with acute heart failure [55]. Other
cardiovascular diseases for which a metabolomic approach has been used include ischaemic
cardiomyopathy [51], coronary artery disease [53], ischaemic stroke [54,64], myocardial
infarction [56], atherosclerosis [58], and heart failure [64]. Furthermore, metabolomic tools
have been used to study the mechanistic pathways involved in the therapeutic effects of
some herbal medicines [62].
3.5. Inborn Error of Metabolism
Inborn errors of metabolism (IEMs) are a heterogeneous group of hereditary disorders
that occur commonly among under-5 children. Traditionally, the diagnosis of IEMs relies
on history taking, clinical examination, and a few biochemical tests. The risk of having
false negatives with the use of this mode of diagnosis is, therefore, remarkably high, and
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examining only a limited section of the pathway of metabolism hinders the discovery
of novel metabolic disorders [59]. An untargeted metabolomic approach that utilises a
single platform rather than targeted metabolite profiling with multiple platforms is now
being recommended in that it is cost-effective and helps in identifying a huge amount of
small-molecular-weight compounds in a single metabolic pathway [60]. In their recent
study, Bonte et al. [60] carried out an untargeted metabolic screening for IEMs using a
semiautomatic sample preparation with a UHPLC–Orbitrap–MS platform on 53 patients
with 33 distinct IEMs and 260 controls. This novel metabolomic approach identified well
over 17,256 compound ions and was able to correctly diagnose IEM in about 90% of cases,
including the detection of mannosyl-β1,4-N-acetylglucosamine, the latest biomarker for
β-mannosidase deficiency [60]. In this study, two diagnoses, however, remained unde-
tected, namely, alkaptonuria and mevalonic aciduria. Except for a few cases of IEMs,
such as argininosuccinate lyase deficiency, dimethylglycine dehydrogenase deficiency, and
GAMT deficiency, Coene and others [59] were also able to accurately diagnose 42 out
of 46 cases using a similar metabolic platform (high-resolution liquid chromatography–
quadrupole time-of-flight (LC-QTOF)), underscoring the vital role of metabolomics in
identifying disease-specific biomarkers among suspected cases of IEMs.
4. Methods
Medline search (linked to medical subject headings—MeSH) conducted on 24 May 2021
for recent studies involving the use of metabolomic tools for biomarker discovery in dis-
ease diagnosis and management yielded 453 records (Table 3). Additional 16 records were
retrieved from other databases and hand-searched references.
Table 3. Summary of the MeSH search terms conducted for the retrieval of recent studies
in metabolomics.
# Searches Results
1 exp metabolomics/ or exp lipidomics/ 19,211




6 2 or 3 or 4 or 5 559,030
7 1 and 6 453
Overall, 26 papers met our inclusion and exclusion criteria. Only original articles
that have identifiable metabolites as biomarkers and that report the use of analytical
tools such as NMR spectroscopy, MS, and FTIR spectroscopy in any of the five selected
disease conditions were included in this study. Other inclusion criteria were the use of a
noninvasive (such as the use of urine, sweat, breath) or minimally invasive (such as the
use of venepuncture) mode of sample collection. As such, review papers, mini reports,
studies in animal subjects, or studies that involved the use of invasive techniques, such
as lumbar puncture, instrumentation, or surgery, were excluded. To capture only recent
developments in this field, we limited our search to the years 2015–2020. With these
inclusion and exclusion criteria in mind, we initially reviewed abstracts of related articles
before retrieving the full texts of papers that were considered relevant for our inclusion
and assessment. We additionally hand-searched references of studies that were initially
accessed for other articles that could be of relevance to our research focus. Finally, only
26 papers were included in this review.
5. Research Limitations
One of our research goals was to be able to delineate what profiling approach is
utilised in each of the studies included in this review. However, only three [45,48,53] of
the identified articles expressly reported utilising untargeted approaches in their studies;
others did not report whether their metabolite profiling study was targeted or untargeted
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(global). Another limitation was paucity of relevant literature, arising from the extremely
strict inclusion/exclusion criteria we employed. This makes it extremely hard to draw far-
reaching, evidenced-based conclusions on the usefulness of metabolomic tools in disease
diagnosis and management.
6. Conclusions and Future Perspective
The field of metabolomics, no doubt, has grown and continues to grow beyond merely
profiling the metabolites in biological samples to identification of novel biomarkers of
disease diagnosis, treatment, progression, and prognosis. While it has provided enormous
insights and better characterisation of biological pathways associated with myriads of
pathophysiological disturbances occurring in living organisms, a lot of factors still hinder
the translation of such research outputs into clinical and industrial applications [70]. The
overarching purpose of this review is to both create an awareness on the relevance of
metabolomic profiling to medical practice and the need to harness resources (human
and material) towards ensuring that laboratory findings (especially as regards biomarker
discovery) become translational. In 2018, experts in metabolomics met at an Australian and
New Zealand Metabolomics Conference (ANZMET 2018) held in Auckland, New Zealand,
where they identified several factors mitigating against the applicability of metabolomic
approaches in the clinics [70]. Among others, poor public perception of metabolomics
as an important field of ‘omics’ science, costs of procuring analytical instruments, the
multidisciplinary nature of metabolomic studies (requiring inputs of experts from different
fields of life sciences), and variability in the modes of data acquisition were noted as
constituting major bottlenecks in the development of translational metabolomics [70].
Equally significant is the fact that metabolomics does not take into consideration the
pivotal role that gender plays as an important determinant of some disease conditions. To
ensure better personalised treatment, experts have equally suggested that metabolomic
studies must take sex into consideration [10]. The number of metabolites identified as
biomarkers for some disease conditions is large, making it difficult to pin down what
metabolites are the most important biomarkers or predictors of disease development,
progression, or therapeutic response. Future research efforts, therefore, must be geared
towards addressing the issue of cost and other challenges that make metabolomics difficult
to apply in the clinics. Funding research and developing algorithms that reduce the number
of diagnostic, therapeutic, or prognostic biomarkers to the barest minimum should also be
vigorously pursued. Finally, we have noted here that the use of a noninvasive or minimally
invasive mode of sample collection for biomarker discovery is possible and holds great
promise for acceptability by patients, especially when combined with analytical tools with
wide metabolite coverage [71]. However, there is a need for the validation and optimization
of these tools to arrive at more accurate and precise metabolic biomarkers that are useful in
this respect.
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Serum Concentrations of Citrate, Tyrosine, 2- and 3- Hydroxybutyrate are Associated with Increased 3-Month Mortality in Acute
Heart Failure Patients. Sci. Rep. 2019, 9, 6743. [CrossRef]
56. Vignoli, A.; Tenori, L.; Giusti, B.; Takis, P.G.; Valente, S.; Carrabba, N.; Balzi, D.; Barchielli, A.; Marchionni, N.; Gensini, G.F.; et al.
NMR-based metabolomics identifies patients at high risk of death within two years after acute myocardial infarction in the
AMI-Florence II cohort. BMC Med. 2019, 17, 3. [CrossRef] [PubMed]
57. Omori, K.; Katakami, N.; Yamamoto, Y.; Ninomiya, H.; Takahara, M.; Matsuoka, T.A.; Bamba, T.; Fukusaki, E.; Shimomura, I.
Identification of Metabolites Associated with Onset of CAD in Diabetic Patients Using CE-MS Analysis: A Pilot Study. J.
Atheroscler. Thromb. 2019, 26, 233–245. [CrossRef]
58. Cardellini, M.; Ballanti, M.; Davato, F.; Cardolini, I.; Guglielmi, V.; Rizza, S.; Pecchioli, C.; Casagrande, V.; Mavilio, M.;
Porzio, O.; et al. 2-hydroxycaproate predicts cardiovascular mortality in patients with atherosclerotic disease. Atherosclerosis 2018,
277, 179–185. [CrossRef] [PubMed]
59. Coene, K.L.M.; Kluijtmans, L.A.J.; Van der Heeft, E.; Engelke, U.F.H.; de Boer, S.; Hoegen, B.; Kwast, H.J.; Van de Vorst, M.;
Huigen, M.C.; Keularts, I.M.; et al. Next-generation metabolic screening: Targeted and untargeted metabolomics for the diagnosis
of inborn errors of metabolism in individual patients. J. Inherit. Metab. Dis. 2018, 41, 337–353. [CrossRef] [PubMed]
60. Bonte, R.; Bongaerts, M.; Demirdas, S.; Langendonk, J.G.; Huidekoper, H.H.; Williams, M. Untargeted metabolomic-based
screening method for inborn errors of metabolism using semi-automatic sample preparation with an UHPLC-Orbitrap-MS
platform. Metabolites 2019, 9, 289. [CrossRef]
61. Mielke, M.M.; Hagen, C.E.; Wennberg, A.M.V.; Airey, D.C.; Savica, R.; Knopman, D.S.; Machulda, M.M.; Roberts, R.O.;
Jack, C.R., Jr.; Petersen, R.C.; et al. Association of Plasma Total tau Level with Cognitive Decline and Risk of mild cognitive
impairment or dementia in the Mayo Clinic study on aging. JAMA Neurol. 2017, 74, 1073–1080. [CrossRef]
62. Yi, M.; Li, Q.; Zhao, Y.; Nie, S.; Wu, N.; Wang, D. Metabolomics study on the therapeutic effect of traditional Chinese medicine
Xue-Fu-Zhu-Yu decoction in coronary heart disease based on LC-Q-TOF/MS and GC-MS analysis. Drug Metab. Pharm. 2019, 34,
340–349. [CrossRef]
63. Lind, L.; Salihovic, S.; Ganna, A.; Sundström, J.; Broeckling, C.D.; Magnusson, P.K.; Pedersen, N.L.; Siegbahn, A.; Prenni, J.;
Fall, T.; et al. A Multi-Cohort Metabolomics Analysis Discloses Sphingomyelin (32:1) Levels to be Inversely Related to Incident
Ischemic Stroke. J. Stroke Cerebrovasc. Dis. 2020, 29, 104476. [CrossRef] [PubMed]
64. Delles, C.; Rankin, N.J.; Boachie, C.; McConnachie, A.; Ford, I.; Kangas, A.; Soininen, P.; Trompet, S.; Mooijaart, S.P.;
Jukema, J.W.; et al. Nuclear magnetic resonance-based metabolomics identifies phenylalanine as a novel predictor of incident
heart failure hospitalisation: Results from PROSPER and FINRISK 1997. Eur. J. Heart Fail. 2018, 20, 663–673. [CrossRef]
65. Chen-Plotkin, A.S.; Albin, R.; Alcalay, R.; Babcock, D.; Bajaj, V.; Bowman, D.; Buko, A.; Cedarbaum, J.; Chelsky, D.;
Cookson, M.R.; et al. Finding useful biomarkers for Parkinson’s disease. Sci. Transl. Med. 2018, 10, eaam6003. [CrossRef]
[PubMed]
66. Shao, Y.; Le, W. Recent advances and perspectives of metabolomics-based investigations in Parkinson’s disease. Mol. Neurodeg.
2019, 14, 3. [CrossRef] [PubMed]
67. Inoue, K.; Tsuchiya, H.; Takayama, T.; Akatsu, H.; Hashizume, Y.; Yamamoto, T.; Matsukawa, N.; Toyo’oka, T. Blood-based
diagnosis of Alzheimer’s disease using fingerprinting metabolomics based on hydrophilic interaction liquid chromatography
with mass spectrometry and multivariate statistical analysis. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2015, 974, 24–34.
[CrossRef]
68. Zetterberg, H.; Burnham, S.C. Blood-based molecular biomarkers for Alzheimer’s disease. Mol. Brain 2019, 12, 26. [CrossRef]
69. Dang, V.T.; Huang, A.; Werstuck, G.H. Untargeted Metabolomics in the Discovery of Novel Biomarkers and Therapeutic Targets
for Atherosclerotic Cardiovascular Diseases. Cardiovasc. Haematolol. Dis. Drug Targets 2018, 18, 166–175. [CrossRef]
70. Pinu, F.R.; Goldansaz, S.A.; Jaine, J. Translational Metabolomics: Current challenges and future opportunities. Metabolites 2019,
9, 108. [CrossRef]
71. Wang, Y.; Liu, S.; Hu, Y.; Li, P.; Wan, J.-B. Current state of the art of mass spectrometry-based metabolomics studies—A review
focusing on wide coverage, high throughput and easy identification. RSC Adv. 2015, 5, 78728–78737. [CrossRef]
